Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Hepatology. 2018 Apr 20;67(6):2271–2286. doi: 10.1002/hep.29715

Fig. 6. Co-targeting AR and mTOR improves anti-HCC activity in vitro.

Fig. 6

(A) Enzalutamide and rapamycin inhibit HCC cell proliferation. SNU423 and MHCC-97L cells were treated with drug carrier (DMSO), enzalutamide (MDV3100), rapamycin, or the combination of two drugs for different times, and measured for cell proliferation by the CCK8. Data (mean ± SD, n = 4) were analyzed by Repeated measures ANOVA; *** p < 0.001.

(B) Enzalutamide and rapamycin inhibit oncogenic growth of HCC cells. Foci formation assay was performed with SNU423 and MHCC-97L cells treated with DMSO, enzalutamide (MDV3100), rapamycin, or their combination.

(C) Quantification of the above results. Data (mean ± SD, n = 4) were analyzed by Repeated measures ANOVA; ***p < 0.001.

(D) Same as Fig. 6A except AR siRNA was used. Data (mean ± SD, n = 4) were analyzed by Repeated measures ANOVA; *** p < 0.001.

(E) Enzalutamide and AZD8055 display strong anti-HCC activity. SNU423 and MHCC-97L cells were treated with DMSO, enzalutamide (MDV3100), AZD8055, or the combination of two drugs for different times, and measured for cell proliferation by the CCK8. Data (mean ± SD, n = 4) were analyzed by Repeated measures ANOVA; *** p < 0.001.

(F) Same as Fig. 6E except PP242 was used. Data (mean ± SD, n = 4) were analyzed by Repeated measures ANOVA; *** p < 0.001.